Company profile

J Ints Bio

Privately held: no public share price (Privately held; pursuing a KOSDAQ technology special listing after an 18bn-won raise in March 2026 but not yet listed. A similarly-named KRX filing belongs to the unrelated J2KBIO Co., Ltd. [resolved 2026-08-05 by resolve-null-is-public; source: https://dealsite.co.kr/articles/158922/075023]) · South Korea

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
JIN-A02
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.